Gastric Electrical Stimulation Reduces Refractory Vomiting in a Randomized Crossover Trial
Philippe Ducrotté(Université de Rouen Normandie), P. Fontaine(Enter (Switzerland)), Sophie Borot, Alfred Penfornis(Enter (Switzerland)), Stanislas Bruley des Varannes(Centre Hospitalier Universitaire de Nantes), Philippe Pouderoux(Centre Hospitalier Universitaire de Nîmes), Étienne Dorval(Centre Hospitalier Universitaire de Tours), G. Charpentier(Centre Hospitalier Sud Francilien), Frank Zerbib(Hôpital Saint-André), Aurélie Schmidt(Geosciences Consultants), Anne‐Marie Leroi(Université de Rouen Normandie), Guillaume Gourcerol(Inserm), Robert Caïazzo(Université de Lille), Maud Robert(Enter (Switzerland)), François Mion(Université Claude Bernard Lyon 1), Michel Dapoigny(University of Clermont Auvergne), Nathalie Donnadieu(Inserm), Samy Hadjadj(Université de Poitiers), Benjamin Castel(Enter (Switzerland)), H. Hanaire(Enter (Switzerland)), Emmanuel Disse(Enter (Switzerland)), Benoît Coffin(Inserm), Quentin Denost(Enter (Switzerland)), Bruno Guerci(Inserm), Lucine Vuitton(Centre Hospitalier Universitaire de Besançon), Gaëtan Prévost(Inserm), F. Borie(Enter (Switzerland)), Bruno Bonaz(Centre Hospitalier Universitaire de Grenoble), Alain Ropert(Hôpital Pontchaillou), Pierre‐Yves Benhamou(Centre Hospitalier Universitaire de Grenoble), N. Jeandidier(Enter (Switzerland)), Romain Altwegg(Université de Montpellier), Henri Duboc(Hôpital Louis-Mourier), E Letessier(Enter (Switzerland)), P. Valensi(Hôpital Jean-Verdier), Emmanuel Huet(Enter (Switzerland)), Nicolas Mathieu(Enter (Switzerland)), Pierre Mathieu(Enter (Switzerland)), Jean Charles Grimaud(Assistance Publique Hôpitaux de Marseille), Sébastien Fontaine(Université Fédérale de Toulouse Midi-Pyrénées), Fabienne Vavasseur(Enter (Switzerland)), Daniela Calabrese(Enter (Switzerland)), Fabián Reche(Enter (Switzerland))
Cited by 158
Related Papers
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
|Gastroenterology|2020|2.1k
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
|Diabetes Care|2017|574
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related Disorders
|Nutrients|2013|493